Clinical and laboratory parameters of the APS patients and the controls
| . | APS patients . | Healthy donors . | P . |
|---|---|---|---|
| Clinical parameters* | |||
| Females/males | 34/9 | 32/6 | |
| Age, y | 48.43 ± 11.68 | 42.88 ± 9.50 | n.s. |
| Arterial thrombosis (%) | 18 (42) | 0 | |
| Venous thrombosis (%) | 7 (16) | 0 | |
| Recurrences (%) | 8 (19) | 0 | |
| Pregnancy morbidity (%) | 19 (44) | 0 | |
| Obesity (%) | 10 (23) | 2 (5) | |
| Increased CIMT (%) | 13 (30) | 2 (5) | |
| Lupus anticoagulant positivity (%) | 29 (67) | 0 | |
| aCL IgG, GPL | 48.64 ± 97.57 | 1.96 ± 2.70 | .007 |
| aCL IgM, MPL | 29.69 ± 53.10 | 10.38 ± 7.58 | .038 |
| Anti-β2GPI, SGU | 41.3 ± 103.0 | 4.07 ± 9.29 | .022 |
| Antiplatelet, ASA/clopidogel (%) | 17 (39) | 0 | |
| Anticoagulant, warfarin/acenocoumarol (%) | 16 (37) | 0 | |
| Hydroxychloroquine (%) | 3(7) | 0 | |
| Laboratory parameters* | |||
| Total cholesterol, mg/dL | 195.88 ± 38.07 | 208.31 ± 31.12 | n.s. |
| Cholesterol HDL, mg/dL | 52.68 ± 13.95 | 63.62 ± 15.45 | n.s. |
| Cholesterol LDL, mg/dL | 118.18 ± 33.93 | 126.45 ± 29.66 | n.s. |
| Triglycerides, mg/dL | 120.61 ± 67.99 | 89.07 ± 57.93 | n.s. |
| C reactive protein, mg/dL | 5.80 ± 10.80 | 1.84 ± 4.81 | n.s. |
| Apolipoprotein A, g/L | 140.19 ± 19.12 | 159.26 ± 28.12 | .019 |
| Apolipoprotein B, g/L | 89.57 ± 19.13 | 89.57 ± 21.64 | n.s. |
| . | APS patients . | Healthy donors . | P . |
|---|---|---|---|
| Clinical parameters* | |||
| Females/males | 34/9 | 32/6 | |
| Age, y | 48.43 ± 11.68 | 42.88 ± 9.50 | n.s. |
| Arterial thrombosis (%) | 18 (42) | 0 | |
| Venous thrombosis (%) | 7 (16) | 0 | |
| Recurrences (%) | 8 (19) | 0 | |
| Pregnancy morbidity (%) | 19 (44) | 0 | |
| Obesity (%) | 10 (23) | 2 (5) | |
| Increased CIMT (%) | 13 (30) | 2 (5) | |
| Lupus anticoagulant positivity (%) | 29 (67) | 0 | |
| aCL IgG, GPL | 48.64 ± 97.57 | 1.96 ± 2.70 | .007 |
| aCL IgM, MPL | 29.69 ± 53.10 | 10.38 ± 7.58 | .038 |
| Anti-β2GPI, SGU | 41.3 ± 103.0 | 4.07 ± 9.29 | .022 |
| Antiplatelet, ASA/clopidogel (%) | 17 (39) | 0 | |
| Anticoagulant, warfarin/acenocoumarol (%) | 16 (37) | 0 | |
| Hydroxychloroquine (%) | 3(7) | 0 | |
| Laboratory parameters* | |||
| Total cholesterol, mg/dL | 195.88 ± 38.07 | 208.31 ± 31.12 | n.s. |
| Cholesterol HDL, mg/dL | 52.68 ± 13.95 | 63.62 ± 15.45 | n.s. |
| Cholesterol LDL, mg/dL | 118.18 ± 33.93 | 126.45 ± 29.66 | n.s. |
| Triglycerides, mg/dL | 120.61 ± 67.99 | 89.07 ± 57.93 | n.s. |
| C reactive protein, mg/dL | 5.80 ± 10.80 | 1.84 ± 4.81 | n.s. |
| Apolipoprotein A, g/L | 140.19 ± 19.12 | 159.26 ± 28.12 | .019 |
| Apolipoprotein B, g/L | 89.57 ± 19.13 | 89.57 ± 21.64 | n.s. |
GPL indicates IgG phospholipid units; MPL, IgM phospholipid units; SGU, standard IgG units; and n.s., not significant.
Except where otherwise indicated, values are the number of subjects and mean ± SD.